Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Exclusion Criteria

• •Limited stage disease
• •PEG or G tubes
• •Hemoptysis
• •Abdominal fistula, perforation, or abscess within the previous 6 months
• •Women who are pregnant or lactating
• •Proteinuria
• •Serious nonhealing wound, ulcer, or bone fracture
• •Evidence of bleeding diathesis or coagulopathy
• •Uncontrolled or serious cardiovascular disease
• •Uncontrolled brain metastasis
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days; Fine needle aspiration within 7 days
• •Patients requiring full-dose anticoagulation must be on a stable dosing schedule prior to enrollment